Published in World J Surg on September 01, 2011
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol (2001) 7.22
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology (1998) 4.29
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest (2001) 2.49
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev (2004) 2.35
Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A (2003) 2.21
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology (2000) 1.61
Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res (2003) 1.58
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res (2002) 1.50
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res (2001) 1.44
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood (2003) 1.44
Signalling shortcuts: cell-surface receptors in the nucleus? Nat Rev Mol Cell Biol (2002) 1.39
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol (2003) 1.38
Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol (2000) 1.37
Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat (2004) 1.25
The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum (2006) 1.25
TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol (1999) 1.24
Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? Breast Cancer Res Treat (2005) 1.24
Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology (2001) 1.20
Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol (2009) 1.20
Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C. J Neurochem (2002) 1.13
TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem (2001) 1.08
Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol (2008) 1.03
Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem (2006) 1.02
Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer (2006) 1.00
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol (2007) 0.98
RANK ligand. Int J Biochem Cell Biol (2006) 0.92
RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. FASEB J (2003) 0.90
Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis. Ann Surg Oncol (2006) 0.88
Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res (2005) 0.84
Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma. Histol Histopathol (2008) 0.80
OPG, RANK and RANK ligand expression in thyroid lesions. Regul Pept (2008) 0.77
Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. Eur J Cancer (2003) 0.75
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) (2014) 2.56
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2009) 1.29
A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J Med Genet (2011) 1.10
Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol (2006) 1.04
Positional statement of the European Society of Endocrine Surgeons (ESES) on modern techniques in pHPT surgery. Langenbecks Arch Surg (2009) 0.95
Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol (Oxf) (2007) 0.93
Post-parathyroidectomy parathyroid hormone levels: the impact on patient survival - a single-centre study in a stage 5 chronic kidney disease population. Nephron Clin Pract (2011) 0.89
Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS One (2013) 0.88
High quality genomic copy number data from archival formalin-fixed paraffin-embedded leiomyosarcoma: optimisation of universal linkage system labelling. PLoS One (2012) 0.84
IgG4-related sclerosing disease clinically mimicking oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 0.83
An aggressive case of pseudomyogenic haemangioendothelioma of bone with pathological fracture and rapidly progressive pulmonary metastatic disease: case report and review of the literature. Skeletal Radiol (2015) 0.82
Paraneoplastic granulomatous vitritis and retinitis as a presentation of recurrent classical Hodgkin's lymphoma. Int Ophthalmol (2010) 0.82
Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab (2014) 0.81
What is the evidence for the management of urethral amyloidosis? A systematic review of the literature. BJU Int (2011) 0.81
MR imaging features of spindle cell lipoma. Skeletal Radiol (2013) 0.80
Enteropathy-associated T-cell lymphoma, lacking MHC class II, with immune-privileged site recurrence, presenting as bilateral ocular vitreous humour involvement - a case report. Histopathology (2012) 0.79
Testicular capillary haemangioma. Br J Hosp Med (Lond) (2012) 0.79
Outcome of operation in patients with adrenocortical cancer invading the inferior vena cava--a European Society of Endocrine Surgeons (ESES) survey. Langenbecks Arch Surg (2011) 0.77
Non healing ulcer of the breast due to calciphylaxis. Breast J (2009) 0.76
Study raises five questions. BMJ (2011) 0.75
Orbital lipofibromatosis in a child: a case report. Orbit (2010) 0.75
Indolent T-Cell Lymphoproliferative Disorder of the Uterine Corpus: A Case Report. Int J Gynecol Pathol (2019) 0.75
An unusual cause of breathlessness. BMJ (2013) 0.75